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Introduction
Cardiovascular disease (CVD) is responsible for more
deaths worldwide than any other condition, and a
large proportion of healthcare budgets are spent on
its treatment and prevention (1). In the USA, for
example, 37% of deaths are caused by CVD, and
costs related to the disease are estimated to be
$401.3 billion for 2006 (2). Deaths caused by CVD
account for 34% of all deaths in Germany, 33% of
deaths in England and Wales, 25% of deaths in Spain
and 21% of deaths in France (2).
The preventative treatment of CVD aims to control
related conditions, such as hypertension, hypercho-
lesterolaemia and diabetes. The worldwide prevalence
of hypertension was estimated to be 26% in 2000, and
this is predicted to rise to 29% by 2025 (3). The ﬁgures
are even higher in economically developed countries
(e.g. Australia, Canada, Germany, Italy, Japan, Spain,
Sweden, the UK and the USA), with an estimated
prevalence of 37% and 42% in 2000 and 2025
respectively. Diabetes affects almost 6% of the world’s
population, and the prevalence of type 2 diabetes is
estimated to be 1–12% in Europe and 7–28% in North
America (4). According to World Health Organisation
(WHO) estimates, hypercholesterolaemia is respons-
ible for 18% of global CVD and 56% of global
ischaemic heart disease (5).
Yet, for hypercholesterolaemia, for example,
< 50% of those qualifying for lipid-modifying
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SUMMARY
Objectives: To review studies on the cost consequences of compliance and⁄or
persistence in cardiovascular disease (CVD) and related conditions (hypertension,
dyslipidaemia, diabetes and heart failure) published since 1995, and to evaluate
the effects of noncompliance on healthcare expenditure and the cost-effectiveness
of pharmaceutical interventions. Methods: English language papers published
between January 1995 and February 2007 that examined compliance⁄persistence
with medication for CVD or related conditions, provided an economic evaluation of
pharmacological interventions or cost analysis, and quantiﬁed the cost conse-
quences of noncompliance, were identiﬁed through database searches. The cost
consequences of noncompliance were compared across studies descriptively.
Results: Of the 23 studies identiﬁed, 10 focused on hypertension, seven on diabe-
tes, one on dyslipidaemia, one on coronary heart disease, one on heart failure and
three covered multiple diseases. In studies assessing drug costs only, increased
compliance⁄persistence led to increased drug costs. However, increased compli-
ance⁄persistence increased the effectiveness of treatment, leading to a decrease in
medical events and non-drug costs. This offset the higher drug costs, leading to
savings in overall treatment costs. In studies evaluating the effect of compli-
ance⁄persistence on the cost-effectiveness of pharmacological interventions,
increased compliance⁄persistence appeared to reduce cost-effectiveness ratios, but
the extent of this effect was not quantiﬁed. Conclusions: Noncompliance with
cardiovascular and antidiabetic medication is a signiﬁcant problem. Increased com-
pliance⁄persistence leads to increased drug costs, but these are offset by reduced
non-drug costs, leading to overall cost savings. The effect of noncompliance on
the cost-effectiveness of pharmacological interventions is inconclusive and further
research is needed to resolve the issue.
Review Criteria
Studies quantifying the cost consequences of
noncompliance with medication for CVD and
related conditions were identiﬁed through searches
of the MEDLINE, EMBASE and NHS Economic
Evaluation databases. A manual search of reference
lists from retrieved papers was also performed.
Qualitative (e.g. type of evaluation, method of
quantifying compliance, source of compliance data)
and quantitative (medication possession ratio) data
were extracted from the study reports.
Message for the Clinic
A review of 23 studies quantifying the cost
consequences of noncompliance with medication
for CVD and related conditions showed that
increased compliance ⁄persistence leads to an
increase in the effectiveness of treatment and a
decrease in medical events. This results in savings
in the overall costs of treating CVD and related
conditions. Increased compliance ⁄ persistence also
appears to reduce cost-effectiveness ratios, but this
effect requires further investigation.
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receive treatment, only about one-third achieve their
blood high-density lipoprotein (HDL) goal and
< 20% achieve their low-density lipoprotein (LDL)
goal (6). A similar pattern of under-treatment is seen
in hypertension and diabetes. For example, a recent
review of national surveys in hypertension among
those aged 35–64 years showed a treatment level
ranging from 25% (England) to 32% (Italy). Even
among patients receiving treatment, the rate of suc-
cessful hypertension control ranged from only 18.7%
in Spain to 40% in England (7). A retrospective,
observational study using data from a General Practi-
tioner prescription database in the UK found even
poorer control of blood pressure, with only 14.2% of
treated patients achieving guideline-determined
blood pressure targets at 1 year (8). Similarly, only
approximately 40% of adults with type 2 diabetes
achieve the goal recommended by the American Dia-
betes Association of glycosylated haemoglobin levels
lower than 7% (9).
The pharmacological treatment of hypertension,
hypercholesterolaemia and diabetes reduces the mor-
bidity and mortality of associated CVD (5,10,11). To
be effective, however, treatment must continue,
sometimes for life, despite an absence of any obvious
symptoms or beneﬁt to the patient. Unfortunately,
lack of symptoms in CVD and related conditions is
one of the most common reasons for patients dis-
continuing treatment or not taking the prescribed
dose at the required intervals. Studies have shown
that poor compliance⁄persistence with medication is
encouraged by the chronic and often asymptomatic
nature of hypertension and hypercholesterolaemia
(12,13). Poor compliance⁄persistence can decrease
the effectiveness of treatment, leading to treatment
failure (11,14,15). This, in turn, leads to an increase
in the use of healthcare resources and an increase in
overall expenditure (16). Similarly, in diabetic
patients, poor compliance⁄persistence is associated
with greater comorbidity, higher hospitalisation rates
and higher mortality rates than those in patients who
are compliant⁄persistent with their antidiabetic med-
ication (17). Furthermore, the World Health Organi-
sation has suggested that noncompliance with
medication is a common problem that leads to com-
promised health beneﬁts and serious economic con-
sequences in terms of wasted time, money and
uncured disease (18). Thus, noncompliance has been
recognised as a serious problem with signiﬁcant eco-
nomic consequences. Although studies have investi-
gated the extent of the economic effect of
noncompliance, such studies have evaluated different
aspects of this effect and have not been designed to
present a complete picture.
This review explores the cost consequences of non-
compliance with pharmaceutical interventions in
hypertension, diabetes, dyslipidaemia and heart fail-
ure. The aim is to evaluate the effects of noncompli-
ance on the different types of expenditure, such as
drug costs, overall healthcare expenditure and pro-
ductivity costs, and to investigate the effect it has on
the cost-effectiveness of pharmaceutical interventions
for CVD and related conditions.
Methods
Deﬁnitions
Two common measures of compliance are adher-
ence (sometimes used as a synonym for compliance)
and persistence. Numerous deﬁnitions have been
used to describe and measure these parameters. In
this review, the deﬁnitions of the International Soci-
ety for Pharmacoeconomics and Outcomes Research
(ISPOR) were used, whereby compliance is deﬁned
as taking medication as prescribed, on time and at
the correct dose, and persistence is deﬁned as the
continuing use (in time) of the prescribed therapy
(19).
Searches
Searches for relevant studies were conducted using
the MEDLINE and EMBASE databases, and the NHS
Economic Evaluation Database (NHSEED). The
search terms used were: cardiovascular, hypertens*,
hyperlipid*, dyslipid*, blood pressure, diabet*, cost*,
economic*, compliance (adherence) and persistence.
A manual search of the reference lists from retrieved
papers was also performed to identify further rele-
vant studies.
Selection criteria
Studies were deemed relevant if they were English
language, human studies published before February
2007; if they involved patients with CVD or related
conditions [hypertension, dyslipidaemia, coronary
heart disease (CHD), heart failure or diabetes]; if
they examined compliance (adherence) and⁄or per-
sistence to pharmaceutical interventions (even if the
primary objective was not to measure compli-
ance⁄persistence); and if they provided an eco-
nomic evaluation or cost analysis and quantiﬁed
the cost consequences of compliance⁄persistence.
Studies published before 1995 were excluded as
results from these earlier studies could not be com-
pared with those from more recent studies because
of changes in treatment patterns (speciﬁcally the
emergence of new treatment options), study meth-
odology and the price of healthcare resources,
including drug prices.
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economic consequence of compliance⁄persistence
was not quantiﬁed; if they examined noncompliance
with antiplatelets, aspirin, digoxin, insulin, non-phar-
maceutical therapies or treatment guidelines; or if
they were reviews of earlier (pre 1995) research
papers, letters to the editor, commentaries or confer-
ence abstracts.
Studies were divided into cost studies and eco-
nomic evaluations. Cost studies examined the effect
of compliance⁄persistence or compliance-enhancing
interventions on the cost of treatment or on produc-
tivity costs, while economic evaluations examined
changes in the cost-effectiveness of an intervention
with different compliance⁄persistence rates using
sensitivity analyses. For the latter, only studies that
used a univariate sensitivity analysis of compli-
ance⁄persistence were selected. When both compli-
ance⁄persistence rates and costs were examined, but
the cost consequences of noncompliance were not
studied, the study was excluded.
Data extraction
Qualitative data extracted from the studies included
the country where the study was performed, the type
of study (retrospective, prospective, model or based
on assumptions), the type of evaluation (cost calcula-
tion, cost study, cost-effectiveness, cost-beneﬁt or
cost-utility analysis), the disease area, the type of
study population, the study setting, the study length,
the deﬁnitions and methods of quantifying compli-
ance and⁄or persistence, and the source of compli-
ance⁄persistence data.
Quantitative data extracted from the studies
included the medication possession ratio (MPR),
which is the most commonly used measure of compli-
ance, and the rate of persistence. The MPR is deﬁned
as the days’ supply of a dispensed prescription divided
by the number of days between prescription reﬁlls
(20). For example, if a patient receives 2 months
(60 days) supply of medication and obtains a pre-
scription reﬁll 80 days later, the MPR would be
60 days of supply divided by 80 days until the next
reﬁll, which is 0.75 or 75%. Persistence is deﬁned by
ISPOR as the accumulation of time from initiation to
discontinuation of therapy (measured by time met-
ric), and is usually identiﬁed by use of a cut-off point.
Analysis
Quantitative analysis was not possible because of the
different methodology used in the different studies,
and difﬁculties in collating cost data from different
countries, where treatment patterns and unit costs
vary. Results from the different studies were, there-
fore, compared descriptively.
Results
Study characteristics
Twenty-three studies that analysed the effect of com-
pliance and⁄or persistence on the cost or cost-effec-
tiveness of treatment were identiﬁed. Of these, 10
focused on hypertension, seven on diabetes, one on
dyslipidaemia, one on CHD, one on heart failure
and three on multiple diseases, including diabetes,
hypertension, hypercholesterolaemia, general heart
disease and heart failure (Table 1). Seventeen of the
studies were cost studies and six were economic eval-
uations. Most were retrospective in design and were
conducted in the USA using administrative claims
databases in managed care organisations (Medicare
and Medicaid; Table 2). Three Italian retrospective
studies used the archives of the Local Health Unit of
Ravenna, a decentralised body of the Italian National
Health Service, which is responsible for providing
health care in the province of Ravenna. Two of these
three studies analysed the same data but in a differ-
ent manner (33,34).
Compliance and persistence: measurement
and results
Three studies in hypertensive patients and one in
diabetic patients gave no compliance⁄persistence
rates (26,35–37) and in another two studies, compli-
ance⁄persistence rates were based on assumptions
(21,40). In most studies, persistent patients were
considered to be those who continued with the same
monotherapy they had been prescribed at the begin-
ning of the study. The three Italian studies (33,34,39)
used a cut-off point of 273 days, with patients on
treatment for < 273 days being considered non-per-
sistent. Another study (32) used a cut-off point of
26 months. Two other studies deﬁned compli-
ance⁄persistence as patients continuing on therapy
for at least 80% of the prescription period or taking
80% of the prescribed dose (25,31). In some studies,
different levels of compliance⁄persistence were
deﬁned according to the percentage of time for
which patients took their medication (24,28,31).
Only one study considered the timing of doses (30).
The rate of compliance or persistence varied
according to the type of study, the patient population,
the method of data collection and the technique used
to measure compliance⁄persistence. In studies assess-
ing the cost-consequences of noncompliance, compli-
ance rates were 45–80% in diabetes, 15–35% in
hypertension, 51–59% in hypercholesterolaemia and
60–96% in other diseases, such as heart failure and
CHD. In CHD, 88% of statins were taken in the pre-
scribed time interval. Persistence rates were measured
only in hypertension, and ranged from 63% to 81%.
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References Country Disease Intervention
Hypothesis⁄study question concerning
compliance
Clark et al. (21) Canada Diabetes ACE inhibitors Should ACE inhibitors be ﬁnanced in type I
diabetic necropathy, assuming that cost is a
major barrier to compliance?
Balkrishnan et al. (22) USA Diabetes Antidiabetics To examine the relationship between health
status, adherence, and healthcare costs
Balkrishnan et al. (23) USA Diabetes Oral antidiabetics vs. thiazolidinediones
(TZD: pioglitazone & rosiglitazone)
To measure the effect of TZD on healthcare
costs and compliance
Hepke et al. (24) USA Diabetes Insulin or oral hypoglycaemic To determine whether compliance affects
well-being and the total costs of diabetes
treatment
Herman et al. (25) USA Diabetes Prevention of type 2 diabetes with the Diabetes
Prevention Program, i.e. lifestyle modiﬁcation
(diet, physical activity) or metformin, 850 mg
o.d.
To estimate the cost-utility of the Diabetes
Prevention Program
Mahoney (26) USA Diabetes Insulin products and oral antidiabetics To evaluate the effects of changing the
formulary status of diabetes drugs and devices
on compliance and healthcare costs
Shenolikar et al. (27) USA Diabetes Pioglitazone To compare treatment compliance and
healthcare costs in African Americans and all
other races
Urquhart (28) USA Hypercholesterolaemia Cholestyramine (six packets per day) vs.
placebo; gemﬁbrozil vs. placebo
To estimate the economic consequences of
compliance
Tsuyuki et al. (29) Canada Heart failure Patient support programme (salt and ﬂuid
restriction, weighing, exercise, medication use,
knowing when to call physician)
To evaluate the effect of a
disease-management programme in heart
failure
Cheng et al. (30) China Coronary heart
disease
Statin (atorvastatin or simvastatin) monotherapy To examine the effects of compliance to statin
therapy on direct medical costs for coronary
heart disease
Rizzo & Simons (31) USA Hypertension Antihypertensives Does noncompliance increase healthcare costs?
Hughes & McGuire (32) UK Hypertension Antihypertensives (ACE inhibitors, beta-blockers,
calcium antagonists, diuretics)
To calculate the costs arising from switching
and discontinuing therapy
Degli Esposti (33)
[reanalysed in
Degli Esposti (34)]
Italy Hypertension Antihypertensives To identify clinical and economic indicators of
pharmacoutilisation of antihypertensives
Mar &
Rodriguez-Artalejo (35)
Spain Hypertension Antihypertensives Cost-effectiveness of treatment for arterial
hypertension, by age, sex, type of drug and
compliance
Urquhart (36) USA Hypertension Electronic monitoring of compliance Basic calculation of monitoring for compliance
Degli Esposti (34)
[reanalysis of
Degli Esposti (33)]
Italy Hypertension Antihypertensives To identify clinical and economic indicators of
pharmacoutilisation of antihypertensives
Co ˆte et al. (37) Canada Hypertension Pharmacy-based health promotion programme
to improve blood pressure control by
improving the quality of prescribing and
adherence to treatment. Pharmacists warned if
patients non-adherent.
To describe the impact of the programme on
costs and beneﬁts
Taylor & Shoheiber (38) USA Hypertension Amlopidine besylate⁄benazepril HCl, single
capsule, ﬁxed dose vs. ACE inhibitor +
dihydropyridine calcium-channel blocker
separately
To evaluate the effect of the combination
product on compliance and costs
Degli Esposti et al. (39) Italy Hypertension Antihypertensives To evaluate how long patients remain on
different antihypertensives
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Overall healthcare costs may be divided into direct
and indirect costs. Direct costs are those relating to
goods, services and other resources that are con-
sumed in the provision of an intervention or in deal-
ing with the side effects or other current and future
consequences. The resources used can be either med-
ical or non-medical. Thus, direct costs include drug
costs, but the major proportion of direct costs is
non-drug-related. Indirect costs refer to productivity
gains or losses relating to illness or death (44). To
calculate the total economic consequences of changes
in compliance⁄persistence, both direct and indirect
costs should be considered.
Most studies in this review examined only direct
costs and four studies considered only medication
costs (28,33,34,39). Indirect costs were considered in
one cost study and three economic evaluations
(35,37,40,41).
Drug costs
The three Italian studies investigated the drug costs
associated with different patterns of compliance and
persistence with antihypertensives (33,34,39). The
average drug costs were highest for patients adding
another drug to their therapeutic regimen and lowest
for occasional users. The costs were signiﬁcantly
higher for persistent patients who either switched
therapies or added another drug to their regimen
compared with those who stayed on the same mono-
therapy throughout the study (Table 3).
In the later Italian study (39), average drug costs
were found to be lower for a combination group
consisting of those remaining on the same therapy
Table 1 (continued)
References Country Disease Intervention
Hypothesis⁄study question concerning
compliance
Rosen et al. (40) USA Hypertension Medicare ﬁrst-dollar coverage vs. no coverage
(current practice) with ACE inhibitor use
increasing from 40% to 60%
To estimate the cost-effectiveness to Medicare
of ﬁrst-dollar (no cost-sharing) coverage of
ACE inhibitors (lisinopril) in patients with
diabetes
Rizzo et al. (41) USA Multiple – hypertension,
heart disease,
depression, type 2
diabetes
Relevant intervention for the disease in
question
To evaluate whether drug coverage and
compliance programmes are cost-effective
saving for employers; how does compliance
modify the cost of treatment?
Plans-Rubio ´ (42) Spain Multiple – prevention of
coronary heart disease
(hypertension,
hypercholesterolaemia,
smoking)
Cholesterol-lowering and antihypertensive
drugs, smoking cessation
How does compliance modify
cost-effectiveness?
Sokol et al. (43) USA Multiple – diabetes,
hypertension,
hypercholesterolaemia,
congestive heart failure
Cardiovascular and antidiabetic drugs To evaluate the impact of medical adherence-
Table 2 Studies according to country, design and type of evaluation
Country
Based on
assumptions Model Prospective Retrospective
Total
Cost
calculation
Cost
study
Economic
evaluation
Cost
study
Economic
evaluation
Cost
study
Economic
evaluation
Canada 1 1 1 3
Italy 33
Spain 2 2
UK 11
USA 1 1 1 3 1 6 13
China 1 1
Total 1 1 4 5 1 10 1 23
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than for those who switched drugs. Among the dif-
ferent types of antihypertensives, angiotensin II
antagonists were associated with the highest percent-
age of continuers (41.7%), resulting in high drug
costs. Average drug costs were also high for calcium-
channel blockers, despite the relatively low continua-
tion rate (26.7%). Conversely, average costs were
relatively low for beta-blockers despite the relatively
high percentage of continuers (36.9%). Diuretics
were associated with the lowest percentage of con-
tinuers (25.9%) and the lowest drug costs (Table 4).
In another study (28), data from two clinical trials
were used to examine compliance and persistence
with cholestyramine and gemﬁbrozil in patients with
hypercholesterolaemia. Drug costs for preventing one
coronary event and for different levels of compliance
and persistence were calculated. The results showed
that although drug costs were higher for more com-
pliant⁄persistent patients, the relative risk of CHD
was lower and the drug costs for preventing one cor-
onary event were very similar for the different levels
of compliance and persistence.
Estimating drug costs only gives an indication of
the effect of noncompliance with the use of different
drug types and acquisition prices; it does not provide
data on the consequences of noncompliance on other
healthcare costs, such as hospitalisation. As a result,
even if a given drug or class of drug is associated
with a low compliance rate (e.g. diuretics), the
increase in drug costs as a result of switching can be
offset by a high proportion of generics and thus rela-
tively low drug costs.
Direct costs
When other, non-drug costs are taken into account,
the results obtained are quite different. The disease-
related and all-cause direct healthcare costs in rela-
tion to compliance were investigated in a multiple
disease study (43). All-cause costs were deﬁned as
any healthcare costs over a 1-year period, while dis-
ease-related costs were considered to be those associ-
ated with the disease only.
For all-cause costs, a high level (80–100%) of
compliance with treatment for diabetes, hypertension
and hypercholesterolaemia was associated with signif-
icantly lower non-drug medical costs than for lower
levels (1–79%) of compliance ($6377 vs. $9363–
15,186 for diabetes; $6570 vs. $7658–10,286 for
hypertension and $4780 vs. $5509–9849 for hyper-
cholesterolaemia; p < 0.05 for high level of compli-
ance vs. lower levels). As these represent the major
proportion of costs, higher levels of compliance with
treatment were associated with lower overall health-
care costs, despite high drug costs. In diabetes,
overall healthcare costs decreased with increasing
compliance, and similar, although nonmonotonic,
decreasing trends were seen in hypertension and
hypercholesterolaemia. The decrease in healthcare
costs with increasing compliance was attributed
mainly to a decrease in the risk of hospitalisation,
which led to a decrease in non-drug medical costs
(Figure 1). Similar associations were seen for disease-
related costs (Figure 2). In diabetes and hypercho-
lesterolaemia, higher levels of compliance were asso-
ciated with lower disease-related costs, despite the
high drug costs (p < 0.05 for 80–100% compliance
vs. lower levels of compliance), again because of a
lower risk of hospitalisation (43). The results for
hypertension followed the same pattern but were not
statistically signiﬁcant.
In the above study, no noticeable trends in overall
costs were observed for congestive heart failure
(CHF) (43). A number of reasons could explain this
Table 3 Average drug costs per patient according to
the pattern of persistence with antihypertensive
medication (34)
Pattern of persistence Average cost per patient (€)
Same therapy 121.51
Combination 274.69
Switching 182.25
Interruption 65.86
Occasional 32.80
Table 4 Annual average drug costs per patient for different antihypertensives according to the pattern of persistence
(39)
Antihypertensive Continuers Switchers Discontinuers Whole study cohort
Diuretics €65.09 €153.10 €8.17 €33.45
Beta blockers €109.29 €158.73 €22.52 €63.40
Calcium-channel blockers €234.63 €199.62 €38.24 €104.43
ACE inhibitors €196.28 €237.53 €34.76 €108.25
Angiotensin II antagonists €326.16 €268.07 €67.10 €201.53
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patients compared with the other disease areas; high
variability in costs; a higher mean chronic disease
index in these patients compared with other disease
areas; higher hospitalisation costs for CHF patients;
higher compliance rates among CHF patients as a
result of the greater severity of their disease and little
change in the risk of hospitalisation with increasing
compliance (Figure 1).
Similarly, a study of compliance with statin mono-
therapy in patients at high risk of CHD showed that
the level of compliance over a 6-month period had
no signiﬁcant effect on direct healthcare costs (30).
In this study, however, compliance data were heavily
skewed and clustered around 100%, possibly due to
the fact that patients who agreed to participate in the
study were more motivated to comply with treat-
ment than patients who did not give consent. Fur-
thermore, the study was too short (6 months) to
enable the effects of statin therapy on disease control
to be properly observed, as the results of a long-term
retrospective study in hypertension have shown that
persistence decreases signiﬁcantly between the ﬁrst
and the second year after the start of pharmacologi-
cal treatment (45), suggesting that a follow-up period
of at least 1 or 2 years is required to properly assess
the effects of noncompliance. In prospective clinical
studies, the drop in persistence may occur even later
because of the strict monitoring of patients and their
higher motivation to comply with treatment.
The ﬁndings in diabetes are supported by the
results of other studies in diabetic patients. In one
study (22), MPR was found to be the strongest pre-
dictor of decreased total annual healthcare costs after
controlling for the type of medication and other
variables, a 10% increase in MPR being associated
with an 8.6% decrease in total annual healthcare
costs (p < 0.001). In another study (27), a 10%
increase in MPR was associated with a 2% decrease
in total annual healthcare costs and a 4% decrease in
diabetes-related annual healthcare costs (p < 0.001
and p < 0.01 for total and diabetes-related costs
respectively). Another study (24) found a threshold
effect, whereby non-drug medical costs increased
until the level of compliance reached 20–39% or
40–59%, and then decreased. The decrease was
caused by fewer emergency room visits and hospitali-
sations after a certain threshold of compliance. This
threshold effect could have been inﬂuenced by the
fact that patients with zero per cent compliance
included not only non-compliers not ﬁlling their
prescription as recommended, but also patients
whose diabetes was controlled through exercise and
diet only, and patients who ﬁlled prescriptions under
another health plan.
Concern over the rising prevalence and costs of dia-
betes to a large (23,000 employees) company in the
USA led the company to redesign its drug beneﬁt
scheme, such that diabetic employees (and their
dependants) were required to pay only 10% of the
cost for both brand-name and generic antidiabetic
medications, rather than 30–50% as before (26). The
rationale behind this was that a predictive model had
shown that poor compliance was linked to increased
healthcare costs, and reducing the cost of treatment to
patients would increase compliance, thereby reducing
complications and healthcare costs. After 2–3 years,
compliance rates had increased, although these were
not presented (26). Average total pharmacy costs
decreased by 7% and emergency department visits
decreased by 26%. Overall, direct healthcare costs per
patient decreased by 6% from 2001 to 2003.
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patients (31), the highest direct costs were incurred
by patients who changed medication by switching or
adding another antihypertensive (US$2142), followed
by non-persistent patients ($735, p = 0.05 vs. ﬁrst
group) and noncompliant patients ($694, p £ 0.001
vs. ﬁrst group). The lowest costs were seen with per-
sistent patients ($341, p £ 0.001 vs. ﬁrst group).
However, the compliance⁄persistence data in this
study were subject to recall bias as they were based
on self-reported compliance⁄persistence. In a UK
study, patients switching medication were again
found to produce the highest drug costs (£218 vs.
£192 for continuers), while continuers produced the
lowest hospital costs (£46 vs. £70 for those switching
medication) (32).
Another study in hypertensive patients compared a
ﬁxed-dose tablet, consisting of a combination of an
angiotensin converting enzyme (ACE) inhibitor and
calcium-channel blocker, with an ACE inhibitor and
a calcium-channel blocker taken separately (38). The
MPR for the ﬁxed-dose tablet was signiﬁcantly
higher than that for the ACE inhibitor and calcium-
channel blocker taken separately (80.8% vs. 73.8%,
p < 0.001). Costs (study drugs, other antihyperten-
sives, other drugs, cardiovascular-related inpatient
costs and total care costs) were signiﬁcantly lower in
the group receiving the combination tablet than in
the group receiving the two drugs separately
(Figure 3).
A study of healthcare costs in heart failure (29)
found that costs were lower for patients who partici-
pated in a support programme than for those who
did not participate in the programme, which
included salt and ﬂuid restriction, regular weighing
and exercise, proper medication use and knowing
when to call the physician. After 6 months of follow-
up, the average MPR for ACE inhibitors was 86.2%
for those participating in the programme and 83.5%
for the control group. The difference between the
compliance rates was not signiﬁcant, but this may
have been due to the short follow-up (only two reﬁll
cycles). Furthermore, frequent contact with the study
coordinator in both groups could have inﬂuenced
the compliance rates. Cardiovascular-related costs
with and without the programme were CAN$2017
and CAN$4548, respectively, while overall costs were
CAN$3691 and CAN$6154 respectively. The reduc-
tion in costs with the patient support programme
was attributed to a signiﬁcant reduction in the total
and average length of cardiovascular-related hospital
stays (341 days vs. 812 days and 6.4 days vs.
11.6 days, respectively; p = 0.003 for both compari-
sons) and a signiﬁcant reduction in cardiovascular-
related emergency room visits (20 vs. 49, p = 0.03).
Indirect costs
Only one of the cost studies investigated both direct
and indirect costs (41). Besides drug costs, this study
examined indirect costs in terms of days missed from
work. The aim was to calculate the overall cost
effects of employer-provided drug coverage and of
increasing compliance to 100%. Over a 1-year period
with average co-payments of 63% in hypertension,
56% in heart disease and 67% in diabetes, employers
acquired $30–46 extra drug costs per employee.
Increased compliance resulted in 3.5–16.1 saved work
days per employee. Assuming an average wage of
$9.32 per hour and fringe beneﬁts of 25%, the bene-
ﬁt from avoiding missed work days was greater than
the extra drug costs paid by the employers, resulting
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Figure 2 Disease-related healthcare costs in relation to the
level of compliance for diabetes (A), hypertension (B) and
hypercholesterolaemia (C) (43)
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($286–$1475 per employee; Table 5). Assuming that
compliance can be increased to 100%, additional
drug costs would amount to $16–$27 per employee,
while the yearly saving in indirect costs would
amount to $191–$962 per employee. However, as
this assumption is not realistic, these savings can
only be interpreted as upper limits of the potential
savings.
Economic evaluations
Of the six economic evaluations, two assessed the
cost-effectiveness of drug coverage using the assump-
tion that high drug costs are a major barrier to com-
pliance⁄persistence and that higher coverage would
increase compliance and persistence with therapy;
two analysed health promotion programmes and two
assessed the economic effects of compliance and per-
sistence in sensitivity analyses. All of the studies apart
from two (25,37) were based on decision models.
Cost-effectiveness of drug coverage
A Canadian study (21) evaluated the effect of provin-
cial payment for ACE inhibitors in patients with type
I diabetes with microalbuminuria. The cost-utility
model ran for 21 years and incorporated direct
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Figure 3 Average annual costs per patient for hypertensive patients taking a combination tablet of an ACE inhibitor
and calcium-channel blocker or separate tablets (38). p < 0.001 for all comparisons, apart from physician visit, where
p = 0.898
Table 5 Beneﬁts to the employer of employer-provided drug coverage and increasing compliance to 100% (41)
Disease area and compliance level
Treatment effect
(days saved)
Employer
costs
Employer
savings
Net
beneﬁt
Hypertension
Average compliance (37% drug coverage) 3.48 $39 $325 $286
Additional beneﬁt if compliance increased to 100% 2.05 $22 $191 $169
Heart disease
Average compliance (44% drug coverage) 7.28 $46 $679 $633
Additional beneﬁt if compliance increased to 100% 4.46 $27 $416 $389*
Diabetes
Average compliance (33% drug coverage) 16.15 $30 $1505 $1475
Additional beneﬁt if compliance increased to 100% 10.32 $16 $962 $946*
*Calculated from the data in the study and not equivalent to the one given in the published report ($370 and $932).
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assumed to be 50% without payment and 67% with
payment. Based on a previous report (46), creatinine
clearance was assumed to decline at a rate of 11%
per year in patients who complied with treatment
and at a rate of 17% per year in noncompliant
patients. Based on these assumptions, a compliance
rate of 34% resulted in an increase in quality
adjusted life-years (QALYs) of 0.147 and a decrease
in annual direct medical costs of CAN$849. Thus,
the provincial payment was dominant (i.e. both
more effective and cost saving). This result was sensi-
tive to the assumptions for compliance, drug costs
and survival times. Provincial payment was the dom-
inant strategy, if compliance increased to at least
66%, and remained under the threshold of
CAN$20,000, if compliance increased to at least
63%. If drug costs were reduced by 50%, provincial
payment was the dominant strategy with a compli-
ance rate of 58% or more.
The above study had many limitations. Namely,
compliance and its effect on efﬁcacy were based on
assumptions; survival was calculated for all diabetes
patients (type I and II disease); dialysis costs were
probably underestimated and the life span of compli-
ant patients was assumed to be similar to that of
noncompliant patients. However, similar conclusions
were reached in a study of Medicare diabetic patients
(40). In this study, the lifetime cost of diabetes in
the drug-beneﬁt scheme was US$110,590 and
$123,973 for compliant and noncompliant patients,
respectively, while the QALYs were 8.82 and 7.67
respectively. In the no-coverage scheme, correspond-
ing costs were $107,914 and $123,973 respectively.
Assuming an increase in compliance of 50% (from
40% to 60%) with ACE inhibitors compared with no
coverage, ﬁrst-dollar coverage proved to be the dom-
inant strategy, resulting in an increase in effectiveness
and a decrease in costs. Such dominance was
observed in 91% of the simulations, while the cost-
effectiveness ratio for ﬁrst-dollar coverage was
< $20,000 in 99% of cases. Besides the higher ACE
inhibitor costs, future unrelated healthcare costs were
also taken into account. These costs were offset by
the medical events prevented.
Health promotion programmes
The economic effects of compliance were evaluated
in sensitivity analyses of data from a clinical trial
investigating the prevention of type 2 diabetes in
patients with impaired glucose tolerance (25). The
Diabetes Prevention Program consisted of lifestyle
modiﬁcation (diet, physical activity), or treatment
with metformin, 850 mg once daily, or placebo. The
incremental cost-effectiveness ratio (ICER) was
$1124⁄QALY for lifestyle intervention and
$31,300⁄QALY for metformin. At the end of the
trial, 72% of metformin and 77% of placebo patients
had taken at least 80% of the prescribed dose.
Assuming that compliance would decrease after the
third year of treatment resulting in a 20–50% reduc-
tion in treatment effectiveness, the ICER would
increase to $3100–7900⁄QALY for lifestyle interven-
tion and to $38,000–52,600⁄QALY for metformin.
A controlled trial evaluated a Canadian pharmacy-
based health promotion programme in hypertension
(37). The programme aimed to improve blood pres-
sure control by improving the quality of prescribing
and compliance with treatment. Although no com-
pliance results were reported, antihypertensive drug
reﬁlls were higher in the intervention group than in
the control group. Assuming that the two groups
required the same average number of reﬁlls, compli-
ance could be considered to be higher in the inter-
vention group. Programme costs were CAN$30.68
per participant. Compared with the control group,
indirect costs for the group participating in the
programme were signiﬁcantly increased (by CAN$40.7
per participant, p < 0.001), while direct costs
signiﬁcantly decreased (by CAN$331.3, p = 0.032),
resulting in a decrease in overall costs of CAN$290.6
(p = 0.06). The net beneﬁts of the programme for the
9-month period of the study were CAN$264.78 per
participant. The internal validity of this study is ques-
tionable, however, because of the signiﬁcant difference
between the two groups with respect to income (more
low income subjects in the group participating in the
programme) and means of transportation (more walk-
ers in the programme group).
Sensitivity analyses
A Spanish study evaluated the different parameters
inﬂuencing the cost-effectiveness of antihypertensives
in patients with stage I and II arterial hypertension
(35). Direct non-medical costs and indirect costs
were incorporated into some of the scenarios in
addition to direct medical costs. The cost of an addi-
tional QALY amounted to €3307–34,516. The cost-
effectiveness ratio decreased with increasing age and
was less in men than in women. The inclusion of
travel and productivity costs increased the cost-effec-
tiveness ratio by 30% in women and by 35% in men.
Assuming a linear relationship between compliance
and efﬁcacy, a decrease in compliance of 50%
resulted in an increase in ICER of 30–50%. This
increase was greater in older patients and was greater
in men than women.
Smaller effects were reported in another Spanish
study investigating the primary prevention of CHD
(42). In this study, the effect of noncompliance with
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only for patients with mild hypertension (diastolic
blood pressure 95–104 mm Hg) and hypercholestero-
laemia (cholesterol level > 7.7 mmol⁄l). The results
showed that a 10% decrease in compliance produced
only a marginal change in the ICER: for treatment
with lovastatin in patients with hypercholesterola-
emia, a 10% decrease in compliance increased the
ICER from $US34,415 to $34,712 per life-year
gained. The corresponding ﬁgure for treatment with
hydrochlorothiazide in patients with mild hyperten-
sion was an increase from $11,906 to $12,025 per
life-year gained.
Discussion
Noncompliance in CVD and related conditions is an
important issue because of the chronic and often
asymptomatic nature of such disease, resulting in
poor disease control and long-term adverse conse-
quences. This review conﬁrms that noncompliance
also has a signiﬁcant effect on costs. However, the
effect differs depending on the type and the range of
costs taken into account. This effect, in turn, inﬂu-
ences the cost-effectiveness of pharmaceutical inter-
ventions for CVD and related conditions.
Effect of noncompliance on cost
Noncompliance appears to have a signiﬁcant effect on
the costs of treatment. High compliance and persis-
tence lead to an increase in drug costs (28,33,34,39),
while low compliance⁄persistence is associated with
increased medical events and hence more physician
visits and hospital admissions, and longer hospital
stays (16,43). The increased use of non-drug resources
with lower levels of compliance and persistence results
in higher overall costs in diabetes (22,24,26,27,43),
hypertension (31,32,43) and hypercholesterolaemia
(43). However, the results of studies in CHD and
heart failure are inconclusive (29,30,43). Noncompli-
ance can also lead to lost productivity because of a
higher number of days missed from work (41).
While the correlation between compliance⁄persis-
tence and inpatient costs seems to be clear, the
relationship between physician visits and compli-
ance⁄persistence is two-sided. For hypertension,
controlled blood pressure reduces the number of
physician visits and hence medical costs. However,
physician visits can also increase compliance⁄persis-
tence by encouraging patients to comply with their
treatment (39).
Effect of compliance on cost-effectiveness
Higher compliance⁄persistence rates appear to lower
the cost-effectiveness ratio in diabetes (21,25,40) and
hypertension (35,37,42). However, the studies
reviewed rarely estimated these effects speciﬁcally,
and if they assessed the effects of compliance⁄persis-
tence quantitatively, they made assumptions (e.g. a
linear relationship between compliance⁄persistence
and effectiveness) to facilitate calculations (35).
Although some of the economic evaluations incor-
porated noncompliance into the cost-effectiveness
calculations, they did not report the numerical effects
of changing the compliance⁄persistence rate. Rather,
they simply reported whether or not it had an
important effect. Thus, the results of these studies
were inconclusive. For example, in a study to deter-
mine the cost-effectiveness of statins in the preven-
tion of CHD, improved compliance did not change
the order of treatments in terms of cost-effectiveness,
but only changed the overall cost-effectiveness of sta-
tin therapy (47). Another study in hypertension
found that although the cost of achieving blood pres-
sure control was sensitive to compliance, the overall
costs of antihypertensive treatment were not (48).
Similarly, in type 2 diabetes, the marginal cost-effec-
tiveness ratio was not sensitive to a decrease in dis-
continuation rates (49).
Fixed-dose combinations
Fixed-dose combinations of different drugs may help
to increase patient compliance⁄persistence in cases
where more than one type of drug is being taken. In
hypertension, such combinations have the potential
to improve disease control and avoid adverse medical
events, thus increasing effectiveness and lowering
non-drug medical costs (38). The improvement in
disease control with the use of ﬁxed-dose combina-
tions can reduce the number of hospitalisations and
physician visits, leading to a decrease in overall
healthcare costs and an improvement in cost-effec-
tiveness (38). Most studies assessing the cost conse-
quences of ﬁxed-dose combinations do not include
estimates of compliance⁄persistence. However, retro-
spective studies have shown that ﬁxed-dose combina-
tions in hypertension can lead to better compliance
and persistence (50–52). This, in turn, leads to better
health outcomes and fewer medical events (53). The
results of one study in diabetes (26) also suggest that
increased use (from 9% to 22%) of ﬁxed-dose com-
binations contributes to decreased healthcare costs.
Factors inﬂuencing the economic effects
of compliance
In most of the studies reviewed, the time interval
analysed was 2 years or less. This may have inﬂu-
enced the results, since the time frame inﬂuences the
effect of noncompliance. In the short term, good
compliance⁄persistence is associated with an increase
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an increase in drug costs. In the long term, however,
medical events are avoided. The point where the sav-
ings from the non-drug costs offset the extra drug
costs (i.e. where increasing compliance⁄persistence
further would be cost-saving) depends on the drug
costs, the avoided events and their costs, and how
far into the future these events take place. The latter
is determined by the course, nature and severity of
the disease.
In addition to the time interval, the type of health-
care system and reimbursement scheme can also
inﬂuence the results. In healthcare systems involving
signiﬁcant patient co-payment, better compli-
ance⁄persistence increases out-of-pocket payments.
Hence, patients bear the higher ﬁnancial burden,
while savings are realised by the third-party payer
(e.g. NHS or insurance company). This could reduce
the patient incentive to be compliant, particularly in
diseases where the consequences of noncompliance
are realised in the very distant future, such as hyper-
tension (1). However, in disease areas where poor
compliance⁄persistence results in immediate or near
deterioration of health, the incentive to be compliant
is greater. In healthcare systems involving insigniﬁ-
cant co-payment, the short-term extra costs and the
long-term savings are realised within the same orga-
nisation, avoiding the higher ﬁnancial burden of bet-
ter compliance⁄persistence. This could encourage
patients to be more compliant, and payers to con-
sider the long-term savings that can be achieved with
higher compliance⁄persistence.
Considerations for future cost studies
and economic evaluations
Retrospective measurement with the aid of claims or
pharmacy databases is a comparatively easy, precise
and quick way of measuring compliance⁄persistence.
However, possession of medication does not neces-
sarily indicate consumption: hoarding and skipping
of medication can occur and the timing of doses
cannot be examined. It is also difﬁcult to know
which drug is responsible for the observed effects
because of the high number of add-on therapies and
because of switching between different drugs. In
addition, retrospective collection of data does not
allow for the selection of patients, so different treat-
ment groups could differ signiﬁcantly in their char-
acteristics. Prospective collection of data (e.g.
alongside clinical trials) allows greater ﬂexibility in
the selection of patients, control groups and compli-
ance⁄persistence measures. However, regular meet-
ings with study investigators, the greater attention
devoted to compliance⁄persistence and the selection
of speciﬁc patients could bias the results, producing
higher compliance⁄persistence rates than those
observed in real life. If feasible, a prospective, real-
world, observational study could represent a more
realistic picture of what happens in a real-world,
usual-care setting.
Most of the studies included in this review used
retrospective data. Accordingly, the most common
measure of compliance used in the different studies
was the MPR. However, compliance rates could not
be compared across studies because of the different
patient populations. As most of the retrospective
studies used the claims databases of managed care
organisations, such as Medicare and Medicaid, the
applicability of the results may be limited to settings
where third party payers are responsible for distrib-
uting health care. Further research is needed to con-
ﬁrm that increased compliance and persistence are
associated with cost savings. Today, payers may
relate increased compliance and persistence to
increased short-term costs because of the impact on
their budget. However, although drug costs alone
may slightly increase, these costs are often off-set by
reduced non-drug costs, which lead to overall cost
savings.
Future research
The association between patient compliance⁄persis-
tence with medication and disease outcomes, such as
cardiovascular or all-cause morbidity and mortality,
has rarely been evaluated outside of the clinical trial
setting. A recent publication from investigators at
Colorado’s Kaiser Permanente showed higher risks
for all-cause hospitalisation and mortality in patients
with diabetes who were non-optimally compliant
with statins, antihypertensives and oral hypoglycae-
mic agents (17). Similar analyses are needed to eval-
uate the relationship between compliance⁄persistence
with antihypertensives and blood pressure outcomes
in patients with hypertension but without signiﬁcant
comorbidities, such as diabetes.
Future research should focus on long-term, real-
world, longitudinal studies to measure the actual
costs and savings associated with increased compli-
ance and persistence, and the impact on positive
health outcomes, such as improved blood pressure,
lipid levels or glycosylated haemoglobin levels. The
most signiﬁcant limitation of retrospective analyses
of administrative claims databases is that the impact
of compliance on clinical outcomes across the differ-
ent drug classes is not obtainable. These limitations
can be overcome using a retrospective electronic
medical record database. However, as drug use is
recorded by prescription order, compliance data is
lacking. Another alternative is to conduct such
research using databases with access to both
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outcomes, such as blood pressure. The Veterans
Health Administration (VHA) health information
system may serve such a purpose. Results from these
studies would provide physicians and decision mak-
ers with additional insights into the various factors
that impact on treatment effectiveness, and may lead
to a paradigm shift with increased focus on the bene-
ﬁts of compliance and persistence rather than on
drug costs alone.
An ongoing study in the VHA is addressing the
question of whether poor compliance with antihyper-
tensive therapies is associated with an increase in
hospitalisation and mortality rates or failure to
improve clinical disease measures, such as blood
pressure outcomes. Data from electronic health
records and pharmacy records will be collected from
the date of the ﬁrst prescription for an antihyperten-
sive. The study timeline will include a 1-year compli-
ance assessment period and a 12- to 18-month
outcomes assessment period. The primary outcome
of the analysis will be a composite end-point of all-
cause hospitalisation or death occurring during the
outcomes assessment period. Secondary outcomes
will include cardiovascular hospitalisation, cardiovas-
cular death, and achievement of blood pressure goals
based on recommended levels for patients with and
without diabetes, during the outcomes assessment
period. It is anticipated that the outcomes of this
study will lend support to the outcomes obtained
from the current review of retrospective studies that
are largely dependent on administrative claims data-
bases and lack clinical outcomes data.
Conclusions
Noncompliance and non-persistence are signiﬁcant
problems in the management of CVD and related
conditions, such as diabetes. The increased drug use
associated with higher compliance and persistence is
associated with an increase in drug costs. These
costs are particularly high for patients switching
therapies. However, better compliance⁄persistence
increases the effectiveness of treatment, leading to a
decrease in future adverse medical events. Fewer
medical events results in lower non-drug costs and,
as the majority of healthcare costs are non-drug
costs, these offset the higher drug expenditures in
the long term, such that a 10% increase in compli-
ance results in a 2–9% decrease in total annual
healthcare costs.
Higher compliance⁄persistence rates also appear to
reduce cost-effectiveness ratios, one study showing
that a 20% decrease in compliance increased the
ICER by $6700⁄QALY. However, most studies
included in this review failed to investigate the extent
of the effect, partly because of a lack of understand-
ing about the relationship between compliance⁄per-
sistence and effectiveness. Thus, the effect of
compliance⁄persistence on cost-effectiveness is
currently inconclusive. Further research into the rela-
tionship between effectiveness, compliance⁄persis-
tence and cost-effectiveness is required to resolve the
issue.
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